M3-Brigade Acquisition Stock (NASDAQ: MBAVW)

Dernières nouvelles pour M3-Brigade Acquisition (NASDAQ:MBAVW) Stock

M3-Brigade Acquisition V Corp is a blank check company.

M3-Brigade Acquisition V Corp

Scotiabank analyst Paul Cheng upgrades EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) from Sector Perform to Sector Outperform and lowers the price target from $150 to $130.

News

Upgrades

Price Target

Analyst Ratings

Scotiabank Upgrades EOG Resources to Sector Outperform, Lowers Price Target to $130

Citigroup analyst Christopher Danely maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Buy and lowers the price target from $235 to $210.

Citigroup Maintains Buy on Texas Instruments, Lowers Price Target to $210

Citigroup analyst Christopher Danely maintains Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) with a Neutral and lowers the price target from $185 to $145.

QCOM

Citigroup Maintains Neutral on Qualcomm, Lowers Price Target to $145

Citigroup analyst Christopher Danely maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and lowers the price target from $52 to $40.

Citigroup Maintains Neutral on ON Semiconductor, Lowers Price Target to $40

Citigroup analyst Christopher Danely maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Buy and lowers the price target from $290 to $220.

NXPI

Citigroup Maintains Buy on NXP Semiconductors, Lowers Price Target to $220

<h3>Gainers</h3>
<ul>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) stock increased by 7.8% to $0.46 during Friday's after-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>CarParts.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTS#NASDAQ">PRTS</a>) stock increased by 6.18% to $0.87. The market value of their outstanding shares is at $50.7 million. </li>
<li>Yunhong Green CTI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHGJ#NASDAQ">YHGJ</a>) stock increased by 5.88% to $1.08. The market value of their outstanding shares is at $27.9 million. </li>
<li>Foresight Autonomous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSX#NASDAQ">FRSX</a>) stock increased by 5.42% to $0.64. The market value of their outstanding shares is at $12.0 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares moved upwards by 5.01% to $0.41. The company's market cap stands at $116.9 million. </li>
<li>Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) shares moved upwards by 4.99% to $7.36. The company's market cap stands at $3.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock fell 10.5% to $1.36 during Friday's after-market session. The company's market cap stands at $14.2 million. </li>
<li>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) stock fell 7.73% to $2.58. The market value of their outstanding shares is at $72.5 million. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) stock fell 7.6% to $0.25. The company's market cap stands at $2.0 million. </li>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) shares declined by 6.94% to $6.31. The company's market cap stands at $80.6 million. The company's, Q4 earnings came out today. </li>
<li>Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) shares decreased by 5.15% to $4.98. The company's market cap stands at $521.6 million. </li>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) stock declined by 5.01% to $0.18. The company's market cap stands at $14.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CURV

FLYE

FRSX

GNLN

NWTN

PLCE

PRTS

SGHC

YHGJ

12 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares rose 15.3% to $0.52 during Friday's after-market session. The market value of their outstanding shares is at $14.5 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock rose 14.18% to $3.3. The market value of their outstanding shares is at $171.4 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock rose 11.52% to $9.29. The company's market cap stands at $4.7 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock increased by 10.95% to $0.95. The company's market cap stands at $3.6 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) stock rose 10.8% to $4.0. The company's market cap stands at $3.6 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) stock increased by 10.11% to $4.9. The market value of their outstanding shares is at $38.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares decreased by 18.5% to $0.11 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Climb Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLYM#NASDAQ">CLYM</a>) shares declined by 11.72% to $1.13. The company's market cap stands at $76.2 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 8.97% to $0.61. The market value of their outstanding shares is at $43.7 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock declined by 7.28% to $1.02. The market value of their outstanding shares is at $4.4 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock fell 7.05% to $1.32. The company's market cap stands at $3.5 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares decreased by 6.67% to $2.03. The company's market cap stands at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ATNF

CLYM

CTOR

KTTA

ONMD

RADX

SNGX

TTNP

VRAX

WGRX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock moved upwards by 8.4% to $0.39 during Friday's after-market session. The company's market cap stands at $7.1 million. </li>
<li>Beam Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) stock moved upwards by 7.95% to $1.9. The company's market cap stands at $28.0 million. As per the press release, Q4 earnings came out today. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares moved upwards by 7.82% to $1.24. The company's market cap stands at $2.5 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock increased by 7.78% to $1.8. The market value of their outstanding shares is at $22.5 million. </li>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) shares rose 6.05% to $3.68. The market value of their outstanding shares is at $47.7 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares moved upwards by 5.97% to $2.29. The company's market cap stands at $76.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock fell 11.0% to $1.05 during Friday's after-market session. The market value of their outstanding shares is at $17.0 million. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) stock decreased by 9.53% to $0.61. The company's market cap stands at $4.5 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock fell 8.35% to $0.38. The market value of their outstanding shares is at $2.3 million. </li>
<li>Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) stock decreased by 7.17% to $3.11. The market value of their outstanding shares is at $24.9 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares fell 6.9% to $0.11. The market value of their outstanding shares is at $15.8 million. </li>
<li>LiqTech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) stock declined by 5.89% to $1.6. The company's market cap stands at $15.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BEEM

BIYA

DFLI

DXST

ILAG

IPDN

LIQT

NEOV

SGBX

12 Industrials Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares increased by 24.4% to $0.28 during Friday's after-market session. The company's market cap stands at $3.7 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) shares increased by 9.31% to $0.88. The company's market cap stands at $1.6 million. </li>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock rose 6.25% to $0.68. The company's market cap stands at $15.7 million. </li>
<li>SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) stock moved upwards by 4.97% to $9.28. The company's market cap stands at $1.3 billion. </li>
<li>nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) shares rose 4.91% to $7.69. The market value of their outstanding shares is at $372.4 million. </li>
<li>Focus Universal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) stock moved upwards by 4.81% to $4.79. The company's market cap stands at $35.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock fell 19.1% to $1.74 during Friday's after-market session. The market value of their outstanding shares is at $44.9 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock decreased by 9.14% to $1.94. The company's market cap stands at $1.1 million. </li>
<li>Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) stock fell 5.77% to $2.45. The market value of their outstanding shares is at $249.0 million. </li>
<li>Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) stock decreased by 5.4% to $1.4. The market value of their outstanding shares is at $68.7 million. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares decreased by 5.02% to $0.76. The company's market cap stands at $5.0 million. </li>
<li>Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) shares fell 4.99% to $7.05. The company's market cap stands at $466.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BZAI

CSIQ

FCUV

LASR

MOVE

ORKT

SEMR

SVRE

TAOP

WRAP

12 Information Technology Stocks Moving In Friday's After-Market Session

16 analysts have shared their evaluations of Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.5, a high estimate of $284.00, and a low estimate of $100.00. Highlighting a 0.21% decrease, the current average has fallen from the previous average price target of $212.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1744405272_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Deckers Outdoor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $100.00&#x7C;$210.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $127.00&#x7C;$185.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Maintains &#x7C;Buy &#x7C; $215.00&#x7C;$215.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $284.00&#x7C;$267.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $185.00&#x7C;$181.00 &#x7C; 
&#x7C;Joseph Civello &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $225.00&#x7C;$235.00 &#x7C; 
&#x7C;Ike Boruchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $210.00&#x7C;$215.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $231.00&#x7C;$190.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $246.00&#x7C;$246.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $240.00&#x7C;$240.00 &#x7C; 
&#x7C;Ashley Helgans &#x7C;Jefferies &#x7C;Raises &#x7C;Hold &#x7C; $200.00&#x7C;$180.00 &#x7C; 
&#x7C;Paul Knight &#x7C;Keybanc &#x7C;Raises &#x7C;Overweight &#x7C; $230.00&#x7C;$213.00 &#x7C; 
&#x7C;Christopher Nardone &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $217.00&#x7C;$182.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $215.00&#x7C;$178.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $240.00&#x7C;$240.00 &#x7C; 
&#x7C;Joseph Civello &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $235.00&#x7C;$230.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Deckers Outdoor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Deckers Outdoor compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Deckers Outdoor's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Deckers Outdoor's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DECK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Deckers Outdoor analyst ratings.</a>
<h2>Get to Know Deckers Outdoor Better</h2>
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2024, Ugg and Hoka accounted for 52% and 42% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships, but also operates e-commerce in more than 50 countries and about 178 company-operated stores. It generated 67% of its fiscal 2024 sales in the United States.
<h3>Deckers Outdoor: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Deckers Outdoor's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 17.1%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 25.0%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Deckers Outdoor's ROE excels beyond industry benchmarks, reaching 18.82%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Deckers Outdoor's ROA stands out, surpassing industry averages. With an impressive ROA of 12.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Deckers Outdoor adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DECK

The Analyst Verdict: Deckers Outdoor In The Eyes Of 16 Experts

7 analysts have shared their evaluations of Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $152.14, along with a high estimate of $166.00 and a low estimate of $125.00. A 6.38% drop is evident in the current average compared to the previous average price target of $162.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744405264_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Churchill Downs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandt Montour &#x7C;Barclays &#x7C;Announces &#x7C;Overweight &#x7C; $125.00&#x7C;- &#x7C; 
&#x7C;Jeffrey Stantial &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $142.00&#x7C;$161.00 &#x7C; 
&#x7C;Jeffrey Stantial &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $161.00&#x7C;$164.00 &#x7C; 
&#x7C;Daniel Politzer &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $158.00&#x7C;$165.00 &#x7C; 
&#x7C;Ben Chaiken &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $148.00&#x7C;$151.00 &#x7C; 
&#x7C;Daniel Politzer &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $165.00&#x7C;$168.00 &#x7C; 
&#x7C;Aaron Hecht &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $166.00&#x7C;$166.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Churchill Downs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Churchill Downs compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Churchill Downs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Churchill Downs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CHDN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Churchill Downs analyst ratings.</a>
<h2>Delving into Churchill Downs's Background</h2>
Churchill Downs Inc is a gaming entertainment, online wagering, and racing company. It operates through three business segments: Live and Historical Racing, Wagering Services, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing. The Wagering Services segment includes the revenue and expenses from pari-mutuel wagers through TwinSpires, companies retail and online sports betting business and Gaming segment includes revenue and expenses for the casino properties and associated racetracks that support the casino license. The Gaming segment generates revenue and expenses from slot machines, video lottery terminals, video poker, HRMs, ancillary food and beverage services, hotel services, commission on pari-mutuel wagering, and racing events.
<h3>Breaking Down Churchill Downs's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Churchill Downs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.23% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Churchill Downs's net margin excels beyond industry benchmarks, reaching 11.49%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Churchill Downs's ROE stands out, surpassing industry averages. With an impressive ROE of 6.58%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Churchill Downs's ROA excels beyond industry benchmarks, reaching 0.99%. This signifies efficient management of assets and strong financial health.
Debt Management: Churchill Downs's debt-to-equity ratio is below the industry average. With a ratio of 4.54, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHDN

What Analysts Are Saying About Churchill Downs Stock

In the last three months, 10 analysts have published ratings on Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $60.3, with a high estimate of $64.00 and a low estimate of $57.00. Witnessing a positive shift, the current average has risen by 3.25% from the previous average price target of $58.40.
<img src="https://www.benzinga.com/files/images/story/2025/1744405254_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Skyward Specialty among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $64.00&#x7C;$63.00 &#x7C; 
&#x7C;Andrew Andersen &#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $59.00&#x7C;$62.00 &#x7C; 
&#x7C;Meyer Shields &#x7C;Keefe, Bruyette &amp; Woods &#x7C;Lowers &#x7C;Outperform &#x7C; $57.00&#x7C;$62.00 &#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $63.00&#x7C;$53.00 &#x7C; 
&#x7C;Reni Benjamin &#x7C;Citizens Capital Markets&#x7C;Maintains &#x7C;Market Outperform&#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Meyer Shields &#x7C;Keefe, Bruyette &amp; Woods &#x7C;Raises &#x7C;Outperform &#x7C; $62.00&#x7C;$60.00 &#x7C; 
&#x7C;Mark Hughes &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $61.00&#x7C;$54.00 &#x7C; 
&#x7C;Matthew Carletti &#x7C;JMP Securities &#x7C;Raises &#x7C;Market Outperform&#x7C; $60.00&#x7C;$53.00 &#x7C; 
&#x7C;Meyer Shields &#x7C;Keefe, Bruyette &amp; Woods &#x7C;Raises &#x7C;Outperform &#x7C; $60.00&#x7C;$59.00 &#x7C; 
&#x7C;Paul Newsome &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $57.00&#x7C;$58.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Skyward Specialty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Skyward Specialty compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Skyward Specialty's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Skyward Specialty's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SKWD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Skyward Specialty analyst ratings.</a>
<h2>Delving into Skyward Specialty's Background</h2>
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
<h3>Skyward Specialty: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Skyward Specialty's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 22.3%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Skyward Specialty's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.81%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.39%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Skyward Specialty's debt-to-equity ratio is below the industry average at 0.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SKWD

Assessing Skyward Specialty: Insights From 10 Financial Analysts

In the latest quarter, 4 analysts provided ratings for Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $147.25, a high estimate of $154.00, and a low estimate of $140.00. Highlighting a 1.17% decrease, the current average has fallen from the previous average price target of $149.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744405242_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Integer Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Richard Newitter &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $140.00&#x7C;$163.00 &#x7C; 
&#x7C;Andrew Cooper &#x7C;Raymond James &#x7C;Announces &#x7C;Outperform &#x7C; $145.00&#x7C;- &#x7C; 
&#x7C;Robert Wasserman &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $150.00&#x7C;$140.00 &#x7C; 
&#x7C;Brett Fishbin &#x7C;Keybanc &#x7C;Raises &#x7C;Overweight &#x7C; $154.00&#x7C;$144.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Integer Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Integer Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Integer Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITGR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Integer Holdings analyst ratings.</a>
<h2>All You Need to Know About Integer Holdings</h2>
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio &amp; Vascular, Cardiac Rhythm Management &amp; Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
<h3>Integer Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Integer Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 11.12%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Integer Holdings's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 7.28%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Integer Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.02%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Integer Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.05%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Integer Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.68.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITGR

What Analysts Are Saying About Integer Holdings Stock

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $76.89, a high estimate of $90.00, and a low estimate of $60.00. This current average reflects an increase of 3.44% from the previous average price target of $74.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1744405228_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Edwards Lifesciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Richard Newitter &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $75.00&#x7C;$78.00 &#x7C; 
&#x7C;Matt Miksic &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $90.00&#x7C;$88.00 &#x7C; 
&#x7C;William Plovanic &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Hold &#x7C; $71.00&#x7C;$68.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $85.00&#x7C;$85.00 &#x7C; 
&#x7C;Adam Maeder &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $73.00&#x7C;$70.00 &#x7C; 
&#x7C;Vijay Kumar &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $73.00&#x7C;$75.00 &#x7C; 
&#x7C;Patrick Wood &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $75.00&#x7C;$70.00 &#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $90.00&#x7C;$75.00 &#x7C; 
&#x7C;Mike Polark &#x7C;Wolfe Research &#x7C;Maintains &#x7C;Underperform &#x7C; $60.00&#x7C;$60.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Edwards Lifesciences compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Edwards Lifesciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Edwards Lifesciences analyst ratings.</a>
<h2>Unveiling the Story Behind Edwards Lifesciences</h2>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
<h3>Edwards Lifesciences's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Edwards Lifesciences's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 9.43%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Edwards Lifesciences's net margin excels beyond industry benchmarks, reaching 27.83%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Edwards Lifesciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.95%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Edwards Lifesciences's ROA excels beyond industry benchmarks, reaching 2.96%. This signifies efficient management of assets and strong financial health.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

In the current market session, Mueller Water Products Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) share price is at $24.53, after a 1.83% increase. Moreover, over the past month, the stock decreased by 9.98%, but in the past year, increased by 61.91%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744405218_0.png" alt="Past Year Chart" />

<h3>Mueller Water Products P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 27.83 in the Machinery industry, Mueller Water Products Inc. has a lower P/E ratio of 27.69. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744405218_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Mueller Water Products

In the latest quarter, 4 analysts provided ratings for LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for LegalZoom.com, revealing an average target of $9.25, a high estimate of $11.00, and a low estimate of $8.00. Witnessing a positive shift, the current average has risen by 15.62% from the previous average price target of $8.00.
<img src="https://www.benzinga.com/files/images/story/2025/1744405214_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive LegalZoom.com. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mario Lu &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $9.00&#x7C;$8.00 &#x7C; 
&#x7C;Ella Smith &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $11.00&#x7C;$9.00 &#x7C; 
&#x7C;Elizabeth Porter &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Underweight &#x7C; $8.00&#x7C;$7.00 &#x7C; 
&#x7C;Ella Smith &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $9.00&#x7C;$8.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to LegalZoom.com. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of LegalZoom.com compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of LegalZoom.com's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of LegalZoom.com's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on LegalZoom.com analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know LegalZoom.com Better</h2>
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
<h3>Financial Milestones: LegalZoom.com's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: LegalZoom.com displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 1.92%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): LegalZoom.com's ROE excels beyond industry benchmarks, reaching 16.76%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): LegalZoom.com's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.56% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.08, LegalZoom.com adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LegalZoom.com Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Citigroup analyst Christopher Danely maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and lowers the price target from $120 to $110.

Citigroup Maintains Buy on Micron Technology, Lowers Price Target to $110

The Trump administration&#8217;s tariffs have introduced new challenges, from rising consumer prices to market volatility, and households may have to adapt their financial approaches. Prioritizing emergency preparedness, resisting reactive investment decisions and adopting disciplined spending habits are key to navigating the turbulent <a href="https://www.benzinga.com/government/regulations/25/04/44774595/stocks-notch-best-week-in-years-as-dip-buying-on-tariff-crisis-gathers-momentum">waters with resilience.&nbsp;</a>
This guide outlines five actionable strategies—from bolstering savings to strategic purchasing—to help maintain financial stability and protect your long-term goals.&nbsp;
Read Next:<a href="https://www.benzinga.com/news/global/25/04/44762211/10-companies-with-exposure-to-trumps-china-tariff-war-ford-tesla-apple-disney-and-more"> 10 Companies With Exposure To Trump&#8217;s China Tariff War: Ford, Tesla, Apple, Disney And More&nbsp;</a>
1. Build a 12-Month Emergency Fund: A strong safety net can shield you from sudden income disruptions, market volatility and potential layoffs triggered by tariff uncertainty. Prioritize expanding your emergency savings to cover 12 months of expenses. 
Personal finance expert Ramit Sethi emphasized this approach <a href="https://www.businessinsider.com/what-to-do-with-money-savings-trump-tariff-market-chaos-2025-4">with</a> Business Insider and noted it's only the second time he has recommended such a large buffer (the first was during COVID-19). 
2. Avoid Panic Selling Investments: Resist the urge to check investment accounts frequently or make impulsive decisions. Sethi compared trying to time the market during turmoil to "walking into a casino after 2 a.m."—likely to lead to costly mistakes. Maintain a long-term perspective and treat investments like "a Thanksgiving turkey in the oven" that requires decades to mature.
3. Proceed Strategically with Major Purchases: If you have planned large expenses like a car, act now while manufacturers offer incentives. Experts advise moving forward if you have stable income and savings because companies like Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and Nissan are offering discounts to offset tariff-related price hikes.
4. Cut Non-Essential Spending: Now is the time to reduce discretionary or nonessential expenses with tariffs likely to raise prices for groceries, clothing and electronics.  Focus on needs over wants, especially if job security is uncertain. Also, avoid locking cash in stockpiled goods; instead, preserve liquidity for essentials like rent or utilities. 
5. Limit Exposure to Market Volatility: Avoid obsessively tracking retirement portfolios. While market dips can feel alarming, experts stress that short-term fluctuations shouldn't derail long-term strategies. Let investments recover naturally, and withdraw only what's necessary to avoid locking in losses.
Navigating the financial turbulence of Trump's tariffs requires a blend of foresight, discipline and adaptability. Economic policies may shift unpredictably, but a proactive approach can turn challenges into opportunities for wealth.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44695907/elon-musk-calls-trump-trade-advisor-peter-navarro-dumber-than-sack-of-bricks-defends-tesla-as-the-most-american-made-cars">Elon Musk Calls Trump Trade Advisor Peter Navarro &#8216;Dumber Than Sack Of Bricks,&#8217; Defends Tesla As &#8216;Most American-Made Cars&#8217; </a></li>
</ul>
Image: Shutterstock

Psychology

Personal Finance

General

5 Smart Money Moves To Thrive Under Tariff Uncertainty

Citigroup analyst Christopher Danely maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $65 to $50.

MCHP

Citigroup Maintains Buy on Microchip Technology, Lowers Price Target to $50

Citigroup analyst Christopher Danely maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $40 to $35.

Comments

M3-Brigade Acquisition

Actualités

Dernières nouvelles pour M3-Brigade Acquisition (NASDAQ:MBAVW) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL